News

HansaBioMed Life Sciences launches Purified Extracellular Vesicles from Human Platelets, developed in collaboration with Finnish Red Cross Blood Service.

Tallinn, Estonia – [03/09/2024] – HansaBioMed Life Sciences, a pioneer in the field of extracellular vesicles (EVs), is proud to announce the launch of its latest product: purified Extracellular Vesicles from Human Platelets. This product, developed in collaboration with the Finnish Red Cross Blood Service (FRCBS), represents a significant advancement in the standardization, control, and purity of EVs from human biofluids available on the market.

The partnership between HansaBioMed and FRCBS, which began in 2021, was established with the shared goal of offering highly characterized and standardized EV material from Blood components to the life science research and development. The newly released EVs from Human Platelets set a new benchmark in the field, offering researchers superior quality and reliability compared to existing EV products.

“The current reference materials in the EV research field require continuous improvement and innovation,” said Dr. Paolo Guazzi, Chief Operating Officer of HansaBioMed Life Sciences. “Our collaboration with FRCBS, a highly experienced blood center, and Dr Saara Laitinen is essential to achieving the next generation of EVs from blood components. These EVs are highly characterized and standardized, both in the preanalytical processing of raw material and downstream EV purification. The final product will be a valuable aid for researchers seeking to unlock the potential of blood derived EVs.”

Extracellular vesicles are very abundant in blood. Blood is known to be very complex fluidic tissue and it contains many other nanoscale particles such as lipoprotein particles that share properties with EVs like size and lipophilicity. These possesse a challenge for purification and manufacturing.

“Blood service has decades of experience in separating cells and other vital components from donated whole blood, which offers a unique expertise and helps include EV isolation into its processes,” said Dr. Laitinen, R&D Manager of FRCBS Research Unit. “To diminish the heterogeneity of the starting material we specially isolate platelet derived EVs from already existing pre-purified platelet concentrates and not from plasma or whole blood. We use excess material from the routine process not risking the clinical use of the donated blood. Our approach is ethically guided and bases on pools of residual components that ensures that the final product is untraceable to individual donors,” she further explains. “HansaBioMed has a strong reputation in high-quality EV products and as a pioneering company in the field appreciates the tedious work behind each patch of EVs. Thus, it was easy to choose HansaBioMed as our collaborator for global distribution. We hope that our blood cell driven EVs will help scientists to learn more of their role in cell-to-cell communication and further help to develop lifesaving therapeutics for the benefit of the patient.”

For more information about HansaBioMed Life Sciences and its products, please visit www.hansabiomed.eu.

About HansaBioMed Life Sciences: HansaBioMed Life Sciences is the oldest company globally that is fully dedicated to the research and development of products in the field of extracellular vesicles. The company is actively involved in research projects that explore the full potential of EVs while providing high-quality products to support nanoparticle and EV research.

About Finnish Red Cross Blood Service: Finnish Red Cross Blood Service (FRCBS) has been performing active scientific research for more than 70 years. Blood Service R&D can be divided into strategic focus areas: the effectiveness of the blood supply chain, cell and tissue compatibility, and the development of products and services. FRCBS holds a solid position in developing EV-based technologies.

Link to PDF version of article.